CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
dasatinibdrug
Likely dose
dasatinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00509041
NCT00509041Phase 2Completed
CompareCT.gov

A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma

Alliance for Clinical Trials in Oncology·interventional·Posted Jul 31, 2007·Updated Aug 11, 2016

In Brief

A Phase 2 clinical trial evaluating dasatinib for Malignant Mesothelioma. Completed, enrolled 46 participants across 37 sites.

Detailed Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 31, 2007
Enrollment StartAug 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.9 years ago

Interventions

dasatinibdrug

50 mg PO bid